Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024
February 29, 2024 at 08:04 am EST
Share
On February 26, 2024, Pacira BioSciences, Inc. and Charles A. Reinhart, III, the Company?s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024. The Company has commenced a search for a successor to Mr. Reinhart. The Company and Mr. Reinhart also agreed to enter into a Consulting Agreement to be effective October 1, 2024, pursuant to which Mr. Reinhart will provide transition services to the Company from October 1, 2024 until June 30, 2025.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
PACIRA BIOSCIENCES, INC. 
